Generalized Myasthenia Gravis (gMG)
Immunology·MeSH: Myasthenia Gravis
Prevalence
20.0 / 100K
Incidence
1.7 / 100K/yr
5 drugs in development·4 companies·6 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| Ultomiris | Xencor Inc (XNCR) |
Phase 2(2)
Phase 1(1)
| Drug | Company |
|---|---|
| CABA-201 | Filana Therapeutics Inc. (FLNA) |
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| CABA-201 | Cabaletta Bio, Inc. (CABA) |
Compare drugs
Frequently asked questions
How many drugs are in development for Generalized Myasthenia Gravis (gMG)?
BioSniper tracks 5 drugs in development for Generalized Myasthenia Gravis (gMG) across 4 companies.
How many clinical trials target Generalized Myasthenia Gravis (gMG)?
There are 6 clinical trials targeting Generalized Myasthenia Gravis (gMG) tracked by BioSniper.
What is the prevalence of Generalized Myasthenia Gravis (gMG)?
The estimated prevalence of Generalized Myasthenia Gravis (gMG) is approximately 20.0 per 100,000 population.
Deep-dive into Generalized Myasthenia Gravis (gMG)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis